Therapeutic advances in acute myeloid leukemia
A Burnett, M Wetzler, B Löwenberg - Journal of clinical oncology, 2011 - ascopubs.org
The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications
Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML)
have revealed a striking heterogeneity with regard to the presence of acquired gene …
have revealed a striking heterogeneity with regard to the presence of acquired gene …
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Chromosomal rearrangements without gene fusions have been implicated in
leukemogenesis by causing deregulation of proto-oncogenes via relocation of cryptic …
leukemogenesis by causing deregulation of proto-oncogenes via relocation of cryptic …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature reviews Clinical …, 2012 - nature.com
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
Pediatric AML: from biology to clinical management
JDE De Rooij, CM Zwaan… - Journal of clinical …, 2015 - mdpi.com
Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
How I treat the older patient with acute myeloid leukemia
G Ossenkoppele, B Löwenberg - Blood, The Journal of the …, 2015 - ashpublications.org
Acute myeloid leukemia (AML) in older patients presents a notable therapeutic challenge to
the clinical hematologist. The clinical biology of AML among patients is highly …
the clinical hematologist. The clinical biology of AML among patients is highly …
Unraveling the molecular pathophysiology of myelodysplastic syndromes
Somatically acquired genetic abnormalities lead to the salient features that define
myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation …
myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation …
Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia
Purpose Acute myeloid leukemia (AML) with inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2)[inv (3)/t
(3; 3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and …
(3; 3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and …
Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology
Context.—A complete diagnosis of acute leukemia requires knowledge of clinical
information combined with morphologic evaluation, immunophenoty** and karyotype …
information combined with morphologic evaluation, immunophenoty** and karyotype …
The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops
S Ottema, R Mulet-Lazaro… - Nature …, 2021 - nature.com
Chromosomal rearrangements are a frequent cause of oncogene deregulation in human
malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia …
malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia …